Personalis Management
Management criteria checks 4/4
Personalis' CEO is Chris Hall, appointed in Dec 2022, has a tenure of 2.75 years. total yearly compensation is $1.54M, comprised of 38.2% salary and 61.8% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $1.25M. The average tenure of the management team and the board of directors is 3.6 years and 3.5 years respectively.
Key information
Chris Hall
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 38.25% |
| CEO tenure | 3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.6yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Personalis: A Growth Inflection Is Imminent, Hold
Nov 28Personalis, Inc. (NASDAQ:PSNL) Released Earnings Last Week And Analysts Lifted Their Price Target To US$8.50
Nov 07
Personalis, Inc.'s (NASDAQ:PSNL) P/S Is Still On The Mark Following 46% Share Price Bounce
Oct 31Revenues Tell The Story For Personalis, Inc. (NASDAQ:PSNL) As Its Stock Soars 29%
Sep 16Is Personalis (NASDAQ:PSNL) A Risky Investment?
Sep 10These Analysts Think Personalis, Inc.'s (NASDAQ:PSNL) Sales Are Under Threat
Aug 10Personalis, Inc. (NASDAQ:PSNL) Stocks Pounded By 28% But Not Lagging Industry On Growth Or Pricing
Aug 02Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 37% But Its P/S Still Looks Reasonable
May 06
NeXT Personal Testing And Moderna Partnership Will Improve Cancer Care
Strategic partnerships and agreements are expected to drive significant revenue and market expansion, particularly in MRD testing and tumor profiling.What You Can Learn From Personalis, Inc.'s (NASDAQ:PSNL) P/S After Its 40% Share Price Crash
Mar 21Personalis, Inc. (NASDAQ:PSNL) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 02Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Feb 04Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 19The Proper Play On Personalis
Oct 28Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump
Sep 14A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb
Jul 25Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower
Apr 19Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story
Mar 02Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story
Dec 18Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?
Dec 04Personalis (NASDAQ:PSNL) Will Have To Spend Its Cash Wisely
Sep 04Investors Holding Back On Personalis, Inc. (NASDAQ:PSNL)
Apr 17The Prognosis For Personalis
Jun 16Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?
Jun 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$74m |
| Jun 30 2025 | n/a | n/a | -US$91m |
| Mar 31 2025 | n/a | n/a | -US$84m |
| Dec 31 2024 | US$2m | US$588k | -US$81m |
| Sep 30 2024 | n/a | n/a | -US$91m |
| Jun 30 2024 | n/a | n/a | -US$81m |
| Mar 31 2024 | n/a | n/a | -US$93m |
| Dec 31 2023 | US$2m | US$534k | -US$108m |
| Sep 30 2023 | n/a | n/a | -US$113m |
| Jun 30 2023 | n/a | n/a | -US$110m |
| Mar 31 2023 | n/a | n/a | -US$114m |
| Dec 31 2022 | US$2m | US$83k | -US$113m |
Compensation vs Market: Chris's total compensation ($USD1.54M) is below average for companies of similar size in the US market ($USD3.47M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Hall (56 yo)
Mr. Christopher M. Hall, also known as Chris, served as Senior Vice President and Head of Diagnostics Business at Personalis, Inc. since October 2022 until December 31, 2022 and serves as its President sin...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3yrs | US$1.54m | 0.17% $ 1.2m | |
| CFO & COO | 6.8yrs | US$1.01m | 0.19% $ 1.4m | |
| Executive VP of R&D and Chief Medical Officer | 4.4yrs | US$989.39k | 0.14% $ 1.0m | |
| Co-Founder and Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Co-Founder and Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Co-Founder and Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Senior VP & Chief Information Officer | less than a year | no data | no data | |
| Senior VP | 5.7yrs | US$674.28k | 0.072% $ 539.9k | |
| Senior Vice President of Genomic Science | 4.3yrs | no data | no data | |
| Senior Vice President of Business Development | 2.9yrs | no data | no data | |
| Senior Vice President of Regulatory | 2.2yrs | no data | no data |
Experienced Management: PSNL's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.8yrs | US$1.54m | 0.17% $ 1.2m | |
| Co-Founder and Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Co-Founder and Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Co-Founder and Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.5yrs | US$90.81k | 0% $ 0 | |
| Independent Chair of the Board | 6.3yrs | US$165.81k | 0.015% $ 113.6k | |
| Independent Director | 6.6yrs | US$110.81k | 0.015% $ 113.6k | |
| Independent Director | 4.8yrs | US$98.31k | 0.029% $ 219.6k | |
| Advisor to the Board | 3yrs | US$5.62m | no data | |
| Independent Director | 3.3yrs | US$93.31k | 0.023% $ 173.5k | |
| Independent Director | 3.8yrs | US$110.49k | 0.024% $ 176.7k |
Experienced Board: PSNL's board of directors are considered experienced (3.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 01:21 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Personalis, Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |
| Patrick Donnelly | Citigroup Inc |